Thrombosis and haemostasis最新文献_第10页

Relationship Between Screening-Detected Atrial Fibrillation and Blood Pressure Levels in Elderly Hypertensive Patients: The OMRON Heart Study. 老年高血压患者筛查出的心房颤动与血压水平之间的关系：欧姆龙心脏研究。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-13 DOI: 10.1055/a-2484-0641

Keitaro Senoo, Mitsuko Nakata, Arito Yukawa, Kohei Kawai, Jun Munakata, Masahiro Makino, Nobunari Tomura, Hibiki Iwakoshi, Tetsuro Nishimura, Satoshi Shimoo, Hirokazu Shiraishi, Satoshi Teramukai, Satoaki Matoba

{"title":"Relationship Between Screening-Detected Atrial Fibrillation and Blood Pressure Levels in Elderly Hypertensive Patients: The OMRON Heart Study.","authors":"Keitaro Senoo, Mitsuko Nakata, Arito Yukawa, Kohei Kawai, Jun Munakata, Masahiro Makino, Nobunari Tomura, Hibiki Iwakoshi, Tetsuro Nishimura, Satoshi Shimoo, Hirokazu Shiraishi, Satoshi Teramukai, Satoaki Matoba","doi":"10.1055/a-2484-0641","DOIUrl":"10.1055/a-2484-0641","url":null,"abstract":"Background: Hypertension is a well-known risk factor for atrial fibrillation (AF) and strokes, but studies assessing screening-detected AF in hypertensive populations and its relationship to the blood pressure (BP) are scarce.Method: We prospectively recruited hypertensive patients (aged ≥60 years) from all over Japan in a decentralized clinical trial. Participants were asked to measure their electrocardiogram (ECG) and BP at home for 3 months with a BP monitor equipped with ECG.Results: Between April 2022 and July 2023, 4,078 hypertensive patients from across the country participated in this study. The mean age was 66.3 ± 5.5 years, and the male proportion was 80.3%. After excluding those with no measurement data (n = 258), AF detection was 5.8% (n = 220/3,820), and the time to AF detection was 3 to 109 days (median 28 days). The mean BP at baseline was 133 ± 14/85 ± 9 mmHg in the morning and 125 ± 14/79 ± 9 mmHg in the evening. AF detection did not significantly differ between the baseline BP categories (log rank test, p = 0.54), with hazard ratios (95% confidence interval) of 0.83 (0.57-1.19), 0.79 (0.55-1.14), and 0.99 (0.59-1.68) for systolic BP (SBP) 135 to 144 and/or diastolic BP (DBP) 85 to 89, SBP 145 to 159 and/or DBP 90 to 99, and SBP ≥ 160 and/or DBP ≥ 100, respectively (SBP ≤ 134 and DBP ≤ 84 as a reference). The results did not change when taking into account the impact of the measurement rates and antihypertensive drugs on AF detection during the observation period.Conclusion: Detection of undiagnosed AF was 5.8% in elderly hypertensives, with no significant differences between the baseline BP categories and no effect of the measurement rate or antihypertensive drugs.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Apixaban and Aspirin in Preventing Portal Vein Thrombosis after Laparoscopic Splenectomy for Cirrhotic Hypersplenism. 阿哌沙班与阿司匹林预防肝硬化脾功能亢进腹腔镜脾切除术后门静脉血栓形成的比较。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-13 DOI: 10.1055/a-2484-0747

Zhaobao Shi, Kunqing Xiao, Tianming Gao, Shengjie Jin, Chi Zhang, Baohuan Zhou, Dousheng Bai, Guoqing Jiang

{"title":"Comparison of Apixaban and Aspirin in Preventing Portal Vein Thrombosis after Laparoscopic Splenectomy for Cirrhotic Hypersplenism.","authors":"Zhaobao Shi, Kunqing Xiao, Tianming Gao, Shengjie Jin, Chi Zhang, Baohuan Zhou, Dousheng Bai, Guoqing Jiang","doi":"10.1055/a-2484-0747","DOIUrl":"https://doi.org/10.1055/a-2484-0747","url":null,"abstract":"Background: Portal vein system thrombosis (PVST) is a frequent and possibly fatal concurrent disorder following splenectomy. The optimal anticoagulant to prevent PVST following splenectomy remains unclear.Objectives: The purpose of this study was to compare the safety and efficacy of apixaban versus aspirin in preventing PVST after laparoscopic splenectomy (LS) for cirrhotic hypersplenism.Methods: In this single-center randomized controlled trial, 80 patients with liver cirrhosis who received LS were randomly allocated to two treatment arms that were treated with apixaban or aspirin for 6 months. The primary effectiveness outcome was PVST formation after LS.Results: We excluded four patients who withdrew from the study. The dynamic incidence of PVST, main and intrahepatic branches of PVST, and splenic vein thrombosis in the 6 postoperative months were all significantly lower in the apixaban treatment arm compared to the aspirin treatment arm (all P <0.001). Significantly lower incidences of PVST, main and intrahepatic branches of PVST, and splenic vein thrombosis in apixaban treatment arm started from postoperative day 7, month 1, and day 7 compared to the aspirin treatment arm respectively (all P <0.05). Multiple logistic regression analysis revealed that apixaban was an independent protective factor for PVST at postoperative month 3, as compared with aspirin (relative risk, 0.057; 95% confidence interval, 0.013-0.248; P <0.001).Conclusion: Compared with aspirin, apixaban could earlier and more effectively prevent PVST following LS for cirrhotic hypersplenism. Apixaban can be chosen as a priority treatment option versus aspirin, contributing to a lower risk of PVST.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An International Consensus Practical Guide on Left Atrial Appendage Closure for the Non-implanting Physician: Executive Summary. 非植入医师关于左心耳闭合的国际共识实用指南：执行摘要。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-10 DOI: 10.1055/a-2469-4896

Tatjana Potpara, Marek Grygier, Karl Georg Haeusler, Jens Erik Nielsen-Kudsk, Sergio Berti, Simonetta Genovesi, Eloi Marijon, Serge Boveda, Apostolos Tzikas, Giuseppe Boriani, Lucas V A Boersma, Claudio Tondo, Tom De Potter, Gregory Y H Lip, Renate B Schnabel, Rupert Bauersachs, Marco Senzolo, Carlo Basile, Stefano Bianchi, Pavel Osmancik, Boris Schmidt, Ulf Landmesser, Wolfram Doehner, Gerhard Hindricks, Jan Kovac, A John Camm

{"title":"An International Consensus Practical Guide on Left Atrial Appendage Closure for the Non-implanting Physician: Executive Summary.","authors":"Tatjana Potpara, Marek Grygier, Karl Georg Haeusler, Jens Erik Nielsen-Kudsk, Sergio Berti, Simonetta Genovesi, Eloi Marijon, Serge Boveda, Apostolos Tzikas, Giuseppe Boriani, Lucas V A Boersma, Claudio Tondo, Tom De Potter, Gregory Y H Lip, Renate B Schnabel, Rupert Bauersachs, Marco Senzolo, Carlo Basile, Stefano Bianchi, Pavel Osmancik, Boris Schmidt, Ulf Landmesser, Wolfram Doehner, Gerhard Hindricks, Jan Kovac, A John Camm","doi":"10.1055/a-2469-4896","DOIUrl":"https://doi.org/10.1055/a-2469-4896","url":null,"abstract":"Many patients with atrial fibrillation (AF) who are in need of stroke prevention are not treated with oral anticoagulation or discontinue treatment shortly after its initiation. Despite the availability of direct oral anticoagulants (DOACs), such undertreatment has improved somewhat but is still evident. This is due to continued risks of bleeding events or ischemic strokes while on DOAC, poor treatment compliance, or aversion to anticoagulant therapy. Because of significant improvements in procedural safety over the years left atrial appendage closure (LAAC), using a catheter-based, device implantation approach, is increasingly favored for the prevention of thromboembolic events in AF patients who cannot have long-term oral anticoagulation. This article is an executive summary of a practical guide recently published by an international expert consensus group, which introduces the LAAC devices and briefly explains the implantation technique. The indications and device follow-up are more comprehensively described. This practical guide, aligned with published guideline/guidance, is aimed at those non-implanting physicians who may need to refer patients for consideration of LAAC.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-escalation of DAPT-A Potential Strategy for Treating Ticagrelor-Related Dyspnea? 社论："心肌梗死患者接受替卡格雷治疗后呼吸困难的临床影响以及改用氯吡格雷的效果"。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI: 10.1055/a-2420-0381

Tobias Geisler

引用次数: 0

Tea Consumption, Milk or Sweeteners Addition, Genetic Variation in Caffeine Metabolism, and Incident Venous Thromboembolism. 茶饮用量、牛奶或甜味剂添加量、咖啡因代谢的遗传变异与静脉血栓栓塞症发病率。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-01 Epub Date: 2024-05-10 DOI: 10.1055/s-0044-1786819

Hao Xiang, Mengyi Liu, Chun Zhou, Yu Huang, Yuanyuan Zhang, Panpan He, Ziliang Ye, Sisi Yang, Yanjun Zhang, Xiaoqin Gan, Xianhui Qin

{"title":"Tea Consumption, Milk or Sweeteners Addition, Genetic Variation in Caffeine Metabolism, and Incident Venous Thromboembolism.","authors":"Hao Xiang, Mengyi Liu, Chun Zhou, Yu Huang, Yuanyuan Zhang, Panpan He, Ziliang Ye, Sisi Yang, Yanjun Zhang, Xiaoqin Gan, Xianhui Qin","doi":"10.1055/s-0044-1786819","DOIUrl":"10.1055/s-0044-1786819","url":null,"abstract":"Objective: The association between tea consumption and venous thromboembolism (VTE) remains unknown. We aimed to evaluate the association between tea consumption with different additives (milk and/or sweeteners) and incident VTE, and the modifying effects of genetic variation in caffeine metabolism on the association.Methods: A total of 190,189 participants with complete dietary information and free of VTE at baseline in the UK Biobank were included. The primary outcome was incident VTE, including incident deep vein thrombosis and pulmonary embolism.Results: During a median follow-up of 12.1 years, 4,485 (2.4%) participants developed incident VTE. Compared with non-tea drinkers, tea drinkers who added neither milk nor sweeteners (hazard ratio [HR]: 0.85; 95% confidence interval [95% CI]: 0.76-0.94), only milk (HR: 0.86; 95% CI: 0.80-0.93), and both milk and sweeteners to their tea (HR: 0.90; 95% CI: 0.81-0.99) had a lower risk of VTE, while those who added only sweeteners to their tea did not (HR: 0.94; 95% CI: 0.75-1.17). Moreover, there was an L-shaped relationship between tea consumption and incident VTE among tea drinkers who added neither milk nor sweeteners, only milk, and both milk and sweeteners to their tea, respectively. However, a nonsignificant association was found among tea drinkers who added only sweeteners to their tea. Genetic variation in caffeine metabolism did not significantly modify the association (p-interaction = 0.659).Conclusion: Drinking unsweetened tea, with or without added milk, was associated with a lower risk of VTE. However, there was no significant association between drinking tea with sweeteners and incident VTE.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"1143-1151"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140903451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID-19. 新冠肺炎患者的蛋白酶激活受体-1 IgG自身抗体。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-01 Epub Date: 2023-11-06 DOI: 10.1055/a-2205-0014

Leander Reinshagen, Vanasa Nageswaran, Harald Heidecke, Kai Schulze-Forster, Anne-Christin Beatrice Wilde, Pegah Ramezani Rad, Wolfgang Poller, Erik Asmus, Szandor Simmons, Wolfgang M Kuebler, Martin Witzenrath, Lajos Markó, Kai Jakobs, Marianna Puccini, David M Leistner, Ursula Rauch-Kröhnert, Nicolle Kränkel, Sofia K Forslund, Ulf Landmesser, Dominik N Müller, Arash Haghikia

引用次数: 0

NLRP3: More than an Inflammasome? NLRP3，不仅仅是一个炎性体。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-01 Epub Date: 2024-09-11 DOI: 10.1055/a-2413-4672

Gabrielle J Pennings

引用次数: 0

Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis. 循环血液生物标志物与癌症患者静脉血栓栓塞风险：系统回顾与元分析》。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-01 Epub Date: 2024-05-20 DOI: 10.1055/a-2330-1371

Danielle Carole Roy, Tzu-Fei Wang, Ronda Lun, Amin Zahrai, Ranjeeta Mallick, Dylan Burger, Gabriele Zitikyte, Steven Hawken, Philip Wells

{"title":"Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis.","authors":"Danielle Carole Roy, Tzu-Fei Wang, Ronda Lun, Amin Zahrai, Ranjeeta Mallick, Dylan Burger, Gabriele Zitikyte, Steven Hawken, Philip Wells","doi":"10.1055/a-2330-1371","DOIUrl":"10.1055/a-2330-1371","url":null,"abstract":"Background: Cancer patients have an increased risk of venous thromboembolism (VTE). Currently, the availability of highly discriminatory prediction models for VTE in cancer patients is limited. The implementation of biomarkers in prediction models might lead to refined VTE risk prediction. In this systematic review and meta-analysis, we aimed to evaluate candidate biomarkers and their association with cancer-associated VTE.Methods: We searched Medline, EMBASE, and Cochrane Central for studies that evaluated biomarkers in adult cancer patients from inception to September 2022. We included studies reporting on VTE after a cancer diagnosis with biomarker measurements performed at a defined time point. Median/mean differences (for continuous measures) and odds ratios (for dichotomous measures) with 95% confidence intervals were estimated and pooled using random-effects models.Results: We included 113 studies in the systematic review. Of these, 50 studies were included in the meta-analysis. We identified two biomarkers at cancer diagnosis (factor VIII and time to peak thrombin), three biomarkers pre-chemotherapy (D-dimer, fibrinogen, and mean platelet volume), and one biomarker preoperatively (platelet count) that had significant median or mean differences. Additionally, we found that hemoglobin <100 g/L and white blood count >11 × 109/L were significantly associated with future VTE risk only when measured at cancer diagnosis. Pre-chemotherapy neutrophil-to-lymphocyte ratio ≥3 and preoperative platelet count ≥400 × 109/L were also found to be associated with future VTE risk.Conclusion: In conclusion, this study identified nine candidate blood biomarkers that may help in optimizing VTE prediction in cancer patients that should be further explored in future studies.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"1117-1133"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141071902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to "Commentary: 'No Genetic Causality between Tobacco Smoking and Venous Thromboembolism: A Two-Sample Mendelian Randomization Study' ". 回复 "评论：'吸烟与静脉血栓栓塞症之间不存在遗传因果关系：双样本孟德尔随机化研究"。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-01 Epub Date: 2024-10-03 DOI: 10.1055/s-0044-1791679

Hong-Cheng Du, Yun-Fei Zheng, Meng-Qi Shen, Bai-Yang Deng

引用次数: 0

The 2024 European Society of Cardiology Guidelines for Diagnosis and Management of Atrial Fibrillation: A Viewpoint from a Practicing Clinician's Perspective. 2024 年欧安会心房颤动诊断和管理指南：临床医生的视角。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2024-12-01 Epub Date: 2024-10-07 DOI: 10.1055/a-2434-9244

Tatjana Potpara, Giulio F Romiti, Christian Sohns

{"title":"The 2024 European Society of Cardiology Guidelines for Diagnosis and Management of Atrial Fibrillation: A Viewpoint from a Practicing Clinician's Perspective.","authors":"Tatjana Potpara, Giulio F Romiti, Christian Sohns","doi":"10.1055/a-2434-9244","DOIUrl":"10.1055/a-2434-9244","url":null,"abstract":"Atrial fibrillation (AF) is a complex disease requiring a multidomain and (usually) long-term management, thus posing a significant burden to patients with AF, practitioners, and health care system. Unlike cardiovascular conditions with a narrow referral pathway (e.g., acute coronary syndrome), AF may be first detected by a wide range of specialties (often noncardiology) or a general practitioner. Since timely initiated optimal management is essential for the prevention of AF-related complications, a concise and simple guidance is essential for practitioners managing AF patients, regardless of their specialty. Guideline-adherent management of patients with AF has been shown to translate to improved patient outcomes compared with guideline-nonadherent treatment. To facilitate guideline implementation in routine clinical practice, a good guideline document on AF should introduce only evidence-based new recommendations, while avoiding arbitrary changes, which may be confusing to practitioners. Herein, we discuss the main changes in the 2024 European Society of Cardiology (ESC) AF Guidelines relative to the previous 2020 ESC document. Whether the updates and new recommendations issued by the new guidelines will translate in high adherence in clinical practice (and hence improved prognosis of patients with AF) will need to be addressed in upcoming years.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"1087-1094"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0